Peak6 LLC Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

PEAK6 LLC bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 9,000 shares of the company's stock, valued at approximately $347,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC purchased a new position in Protagonist Therapeutics in the 4th quarter valued at approximately $38,000. Covestor Ltd grew its stake in Protagonist Therapeutics by 5,200.0% during the 4th quarter. Covestor Ltd now owns 1,643 shares of the company's stock worth $63,000 after purchasing an additional 1,612 shares in the last quarter. KBC Group NV increased its holdings in Protagonist Therapeutics by 54.4% during the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after purchasing an additional 737 shares during the period. Nisa Investment Advisors LLC raised its position in Protagonist Therapeutics by 10.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock valued at $121,000 after purchasing an additional 295 shares in the last quarter. Finally, Cibc World Markets Corp purchased a new position in shares of Protagonist Therapeutics in the 4th quarter valued at about $211,000. Hedge funds and other institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Trading Down 0.8 %

Shares of Protagonist Therapeutics stock traded down $0.36 during trading on Friday, reaching $44.49. The company's stock had a trading volume of 634,255 shares, compared to its average volume of 857,272. The company has a 50-day moving average price of $45.58 and a two-hundred day moving average price of $42.84. Protagonist Therapeutics, Inc. has a fifty-two week low of $24.78 and a fifty-two week high of $60.60. The firm has a market cap of $2.73 billion, a PE ratio of 16.73 and a beta of 2.30.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings data on Friday, February 21st. The company reported $1.98 EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The company had revenue of $170.64 million for the quarter, compared to analyst estimates of $56.65 million. On average, analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Arturo Md Molina sold 30,514 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the transaction, the insider now directly owns 83,892 shares in the company, valued at $4,676,140.08. The trade was a 26.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director William D. Waddill sold 4,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $54.25, for a total value of $217,000.00. Following the completion of the sale, the director now directly owns 13,130 shares of the company's stock, valued at $712,302.50. This represents a 23.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 66,532 shares of company stock valued at $3,665,786. 5.40% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently weighed in on PTGX shares. JMP Securities reaffirmed a "market outperform" rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a report on Friday, February 7th. BTIG Research set a $73.00 target price on shares of Protagonist Therapeutics in a research note on Monday, March 3rd. Truist Financial raised their price target on Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a research note on Tuesday, March 11th. Wedbush reissued an "outperform" rating and set a $70.00 target price on shares of Protagonist Therapeutics in a research report on Friday, March 28th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Protagonist Therapeutics in a report on Thursday, April 10th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $65.44.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.